Treatment for substance use reduces depression for many adolescents and young adults with both problems

Washington, DC, March 29, 2022 – A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, reports that, among youth with substance use and depression, a significant proportion show early improvements in depression during their treatment for substance use. Youth who are using cannabis less frequently prior to treatment and those without conduct disorder are more likely to experience early depression improvement.

“The combination of alcohol or cannabis use and depression is a significant problem in adolescents and young adults. In addition to the negative outcomes associated with substance use, like automobile accidents and academic problems, those with both conditions tend to have longer episodes of depression, more substance-related problems, and, most importantly, an increased risk for suicidal behavior,” said lead author John Curry, PhD, Professor Emeritus in the Department of Psychiatry & Behavioral Sciences at Duke University, Durham, NC. “Yet there is no standard approach to treating them, and they are often treated in two separate systems of care.”

Earlier studies have shown that some of these young people will show significant improvement in depression during treatment for substance use alone, suggesting that if that improvement is sustained, they may not need additional depression treatment. Based on this evidence, the researchers tested an adaptive approach in which everyone received substance use treatment. Yet, if they were still depressed after a month, they would receive additional depression treatment either with the same therapist or in the community.

“This approach allowed us to examine two different approaches to depression treatment for youth with substance use,” said Dr. Curry. “We also wanted to discover what proportion of the youth would have an early depression response during substance use treatment and what factors predicted it.”

Across two sites, a sample of 95 youths between the ages of 14 and 21 with alcohol or cannabis use and depressive symptoms received up to 12 sessions of cognitive behavior therapy (CBT) for substance use over 14 weeks. Before treatment, they completed measures of psychiatric diagnoses, alcohol or cannabis use, and severity of depression. Early depression response was defined as a 50% reduction in symptoms by week 4 of treatment. Those without early depression response were randomized to add either CBT for depression with the same therapist or depression treatment in the community.

Thirty-five participants (37%) demonstrated early depression response. Predictors of early depression response were lower frequency of cannabis use at baseline and lack of a conduct disorder diagnosis. No other variables—including demographic characteristics, severity of depression, or other psychiatric diagnoses—were predictors. Frequency of drinking, heavy drinking, and cannabis use declined over the full course of treatment for all participants. Among those without early depression response, depression improved significantly with either additional CBT or community treatment, with no difference between treatments.

“This treatment study emphasizes the importance of recognizing the heterogeneity of youth with substance use and co-occurring disorders such as depression, including the different trajectories of their responses to treatment,” said lead author Yifrah Kaminer, MD, MBA, Professor Emeritus of Psychiatry at the University of Connecticut, Storrs, CT. “An important finding is that the level of cannabis use affects the trajectory of change in depression during treatment. Additional examination of potential biological markers or other predictors of treatment response is of paramount importance for developing cost-effective interventions.”

Additional analyses will examine the course of depression and substance use after treatment, and whether the young people whose depression responded to substance use treatment continue to remain less depressed. Given the relatively small sample, it will be important to replicate the study’s findings in other samples. Future research is needed to investigate the factors that underlie the relationship between substance use and depression over time.

---

Notes for editors
The article is "Adaptive Treatment for Youth With Substance Use and Depression: Early Depression Response and Short-term Outcomes,” by John F. Curry, PhD, Yifrah Kaminer, MD, David B. Goldston, PhD, Grace Chan, PhD, Karen C. Wells, PhD, Rebecca H. Burke, BA, Adrienne Banny Inscoe, PhD, Allison E. Meyer, PhD, Shayna M. Cheek, MA (https://doi.org/10.1016/j.jaac.2021.07.807). It currently appears on the JAACAP Articles In Press page and will appear in the Journal of the American Academy of Child and Adolescent Psychiatry, volume 61, issue 4 (April 2022), published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact the JAACAP Editorial Office at support@jaacap.org or +1 202 587 9674. Journalists wishing to interview the authors may contact John F. Curry, PhD, e-mail: john.curry@duke.edu

About JAACAP
Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.

The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com